News-Pyrotech

News

Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development

2026-09-01
Breakthrough: China's NMPA authorizes the world's first selective GSDMD inhibitor to enter clinical trials, overturning the long-held view that GSDMD is undruggable

2026-08-04
Pyrotech Therapeutics Announces the Completion of Hundreds of Millions of RMB in Pre-B Financing

2026-07-03
SMART Symposium on Pyroptosis and Gasdermin Biology

2026-02-26
Pyrotech Therapeutics Announces Clinical Approval in China for First-in-Class Tumor Immunotherapy Drug with Novel Mechanism

2025-03-21
Pyrotech Therapeutics Announces the Completion of Hundreds of Millions of RMB in Series A+ Financing

2024-05-24

Media Contacts

+8610 8193 8000

info@pyrotech.com